Abstract
To investigate whether the serum antibody responses to human papillomavirus (HPV) in cervical carcinoma were related to the clinical and histopathological features of the tumors and how the antibody responses were affected by treatment, pretreatment serum samples from 66 patients with carcinoma of the cervix were studied for the presence of IgA or IgG responses against six defined HPV epitopes. Posttreatment serum samples were drawn from the same patients 2–24 months after initiation of treatment. There was no significant correlation between pretreatment level of any of the investigated antibodies and clinical stage or differentiation of tumor. For the IgA responses to the epitopes 245∶16 and 245∶18 in the E2 protein there was a significant correlation between an increased pretreatment antibody level and a shortened survival. A high pretreatment value of IgA against 245∶16 was also associated with the absence of any complete response after therapy. The antibody levels declined dramatically after therapy for most of the antigens studied. However, this decline was seen both among the 53 patients with complete remission and among the 13 patients with remaining or progressive disease. Thus, the investigated serological responses were not useful as tumor markers, since patients with progressive, latestage disease may fail to mount an antibody response to these proteins. However, pretreatment levels of the serological responses to the HPV epitopes 245∶16 and 245∶18 were associated with prognosis in cervical cancer.
Key words: Cervical cancer, Human papillomavirus, Serology, Tumor markers, Prognostic markers
References
- 1.Dillner J. Mapping of linear epitopes of the human papillomavirus type 16: The E1, E2, E4, E5, E6 and E7 open reading frames. Int J Cancer. 1990;46:703. doi: 10.1002/ijc.2910460426. [DOI] [PubMed] [Google Scholar]
- 2.Dillner J. Antibody responses to defined epitopes in cervical neoplasia. Papillomavirus Rep. 1994;5:35. [Google Scholar]
- 3.Dillner J, Lenner P, Lehtinen M, Eklund C, Heino P, Wiklund F, Hallmans G, Stendahl U. A population-based seroepidemiological study of cervical cancer. Cancer Res. 1994;54:134. [PubMed] [Google Scholar]
- 4.Dyson N, Howley PM, Munger K, Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243:934. doi: 10.1126/science.2537532. [DOI] [PubMed] [Google Scholar]
- 5.Koutsky LA, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327:1272. doi: 10.1056/NEJM199210293271804. [DOI] [PubMed] [Google Scholar]
- 6.Lehtinen M, Leminen A, Kuoppala T, Tiikainen M, Lehtinen T, Lehtovirta P, Punnonen R, Vesterinen E, Paavonen J. Pre- and posttreatment serum antibody responses to HPV 16 E2 and HSV 2 ICP8 proteins in women with cervical carcinoma. J Med Virol. 1992;37:180. doi: 10.1002/jmv.1890370306. [DOI] [PubMed] [Google Scholar]
- 7.Lehtinen M, et al. Evaluation of serum antibody response to a newly identified B-cell epitope in the minor nucleocapsid protein L2 of human papillomavirus type 16. Clin Diagn Virol. 1993;1:153. doi: 10.1016/0928-0197(93)90010-3. [DOI] [PubMed] [Google Scholar]
- 8.Mann V, et al. Occurrence of IgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls. Cancer Res. 1990;50:7815. [PubMed] [Google Scholar]
- 9.Muller M, et al. Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16 associated invasive cervical carcinoma. Virology. 1992;187:508. doi: 10.1016/0042-6822(92)90453-v. [DOI] [PubMed] [Google Scholar]
- 10.Schiffman MH, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993;85:958. doi: 10.1093/jnci/85.12.958. [DOI] [PubMed] [Google Scholar]
- 11.Van Doornum GJJ, Prins M, Pronk L, Coutinho RA, Dillner J. Antibody levels against defined epitopes of human papillomavirus type 16 in relation to genital and anorectal presence of HPV DNA: a prospective study. Clin Diagn Lab Immunol. 1994;1:633. doi: 10.1128/cdli.1.6.633-639.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248:76. doi: 10.1126/science.2157286. [DOI] [PubMed] [Google Scholar]
- 13.Zur Hausen H. Viruses in human cancers. Science. 1991;254:1167. doi: 10.1126/science.1659743. [DOI] [PubMed] [Google Scholar]